Half-Life
"Half-Life" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity.
Descriptor ID |
D006207
|
MeSH Number(s) |
G01.910.405
|
Concept/Terms |
Half-Life- Half-Life
- Half Life
- Half-Lifes
- Halflife
- Halflifes
|
Below are MeSH descriptors whose meaning is more general than "Half-Life".
Below are MeSH descriptors whose meaning is more specific than "Half-Life".
This graph shows the total number of publications written about "Half-Life" by people in this website by year, and whether "Half-Life" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1984 | 0 | 1 | 1 | 1986 | 0 | 2 | 2 | 1987 | 0 | 1 | 1 | 1994 | 0 | 1 | 1 | 1997 | 0 | 2 | 2 | 1998 | 0 | 1 | 1 | 2002 | 0 | 1 | 1 | 2004 | 0 | 2 | 2 | 2005 | 0 | 1 | 1 | 2007 | 0 | 1 | 1 | 2009 | 0 | 2 | 2 | 2016 | 0 | 1 | 1 | 2020 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Half-Life" by people in Profiles.
-
Goldberg JA, Nguyen H, Kumar V, Spencer EJ, Hoyer D, Marshall EK, Cmolik A, O'Shea M, Marshall SH, Hujer AM, Hujer KM, Rudin SD, Domitrovic TN, Bethel CR, Papp-Wallace KM, Logan LK, Perez F, Jacobs MR, van Duin D, Kreiswirth BM, Bonomo RA, Plummer MS, van den Akker F. A ?-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli. J Med Chem. 2020 06 11; 63(11):5990-6002.
-
Simpson ML, Desai V, Maro GS, Yan S. Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products. J Manag Care Spec Pharm. 2020 Apr; 26(4):504-512.
-
Klamroth R, Simpson M, von Depka-Prondzinski M, Gill JC, Morfini M, Powell JS, Santagostino E, Davis J, Huth-Kühne A, Leissinger C, Neumeister P, Bensen-Kennedy D, Feussner A, Limsakun T, Zhou M, Veldman A, St Ledger K, Blackman N, Pabinger I. Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate(®) ) in patients with severe haemophilia A. Haemophilia. 2016 Sep; 22(5):730-8.
-
Arif SA, D'Souza J, Gil M, Gim S. Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. Am J Health Syst Pharm. 2015 Oct 01; 72(19):1615-22.
-
Berger M, Pinciaro PJ, Althaus A, Ballow M, Chouksey A, Moy J, Ochs H, Stein M. Efficacy, pharmacokinetics, safety, and tolerability of Flebogamma 10% DIF, a high-purity human intravenous immunoglobulin, in primary immunodeficiency. J Clin Immunol. 2010 Mar; 30(2):321-9.
-
Molnar J, Somberg JC. The clinical pharmacology of ethacrynic acid. Am J Ther. 2009 Jan-Feb; 16(1):86-92.
-
Patel TV, Robinson K, Singh AK. Is it time to reconsider subcutaneous administration of epoetin? Nephrol News Issues. 2007 Oct; 21(11):57, 59, 63-4 passim.
-
Ranade VV, Somberg JC. Chiral cardiovascular drugs: an overview. Am J Ther. 2005 Sep-Oct; 12(5):439-59.
-
Gouveia CH, Christoffolete MA, Zaitune CR, Dora JM, Harney JW, Maia AL, Bianco AC. Type 2 iodothyronine selenodeiodinase is expressed throughout the mouse skeleton and in the MC3T3-E1 mouse osteoblastic cell line during differentiation. Endocrinology. 2005 Jan; 146(1):195-200.
-
Rice PJ, Lockhart BE, Barker LA, Adams EL, Ensley HE, Williams DL. Pharmacokinetics of fungal (1-3)-beta-D-glucans following intravenous administration in rats. Int Immunopharmacol. 2004 Sep; 4(9):1209-15.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|